<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Femasys Inc — News on 6ix</title>
<link>https://6ix.com/company/femasys-inc</link>
<description>Latest news and press releases for Femasys Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/femasys-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683569d778dffbe2df0f1edf.webp</url>
<title>Femasys Inc</title>
<link>https://6ix.com/company/femasys-inc</link>
</image>
<item>
<title>Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-launches-femaseedr-complete-for-obgyns-at-acog-2026</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-launches-femaseedr-complete-for-obgyns-at-acog-2026</guid>
<pubDate>Wed, 22 Apr 2026 13:00:00 GMT</pubDate>
<description>Expanding commercialization of first-line fertility treatment in the OB/GYN office to increase patient accessATLANTA, April 22, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the commercial launch of FemaSeed Complete, a comprehensive fertility solution that enables OB/GYNs to perform first-line insemination entirely wi</description>
</item>
<item>
<title>Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-drives-international-growth-with-israeli-market-entry-for-fertility-portfolio</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-drives-international-growth-with-israeli-market-entry-for-fertility-portfolio</guid>
<pubDate>Thu, 16 Apr 2026 13:00:00 GMT</pubDate>
<description>-- Partnership with AMI Technologies Positions FemaSeed® as a First-Line Infertility Treatment in Israel, Expanding Market Access to Innovative Fertility Solutions -- ATLANTA, April 16, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today a strategic partnership with AMI Technologies to introduce and commercialize its fertili</description>
</item>
<item>
<title>Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-appoints-john-canning-as-chief-operating-officer-to-drive-operational-execution-and-advance-commercial-growth-9</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-appoints-john-canning-as-chief-operating-officer-to-drive-operational-execution-and-advance-commercial-growth-9</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent</description>
</item>
<item>
<title>Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-announces-financial-results-for-year-ended-december-31-2025-and-provides-corporate-update-3</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-announces-financial-results-for-year-ended-december-31-2025-and-provides-corporate-update-3</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>-- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc® U.S. approval -- ATLANTA, March 31, 2026 (GLOBE</description>
</item>
<item>
<title>Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-appoints-dr-kenneth-d-eichenbaum-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-appoints-dr-kenneth-d-eichenbaum-to-board-of-directors</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent</description>
</item>
<item>
<title>Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-advances-fembloc-toward-us-approval-with-initiation-of-pivotal-trial-enrollment-6</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-advances-fembloc-toward-us-approval-with-initiation-of-pivotal-trial-enrollment-6</guid>
<pubDate>Tue, 10 Mar 2026 13:00:00 GMT</pubDate>
<description>-- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ATLANTA, March 10, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the initiation of patient enrollment in the FINALE pivotal clinical trial eva</description>
</item>
<item>
<title>Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Fri, 27 Feb 2026 22:26:00 GMT</pubDate>
<description>ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has granted to two new non-executive employees who began their employment with Femasys in February 2026 options to purchase 185,000 shares of Femasys common stock. These inducement grants were granted at an exercise price per share of $0.50 and $0.57, equal to the</description>
</item>
<item>
<title>Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-announces-femblocr-permanent-birth-control-has-achieved-mdsap-certification-advancing-global-market-access</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-announces-femblocr-permanent-birth-control-has-achieved-mdsap-certification-advancing-global-market-access</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>-- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven track record of compliance -- ATLANTA, Feb. 26, 2026 (GLOBE</description>
</item>
<item>
<title>Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-receives-ama-cpt-editorial-panel-approval-for-new-category-iii-cpt-code-for-femaseed-intratubal-insemination</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-receives-ama-cpt-editorial-panel-approval-for-new-category-iii-cpt-code-for-femaseed-intratubal-insemination</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-expands-european-commercial-footprint-141500648</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-expands-european-commercial-footprint-141500648</guid>
<pubDate>Tue, 03 Feb 2026 14:15:00 GMT</pubDate>
<description>-- Multi-Product Distribution Agreement Marks Continued Commercial Momentum in Europe --ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland. The agreement includes FemBloc Permanent Birth</description>
</item>
<item>
<title>Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-granted-180-day-extension-140000355</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-granted-180-day-extension-140000355</guid>
<pubDate>Wed, 14 Jan 2026 14:00:00 GMT</pubDate>
<description>ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, today announced that on January 13, 2026, it received notification from The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq approved the Company's request for an additional 180-calendar day extension to regain compliance with the minimum closing bid price</description>
</item>
<item>
<title>Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-announces-partnership-refuah-health-140000535</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-announces-partnership-refuah-health-140000535</guid>
<pubDate>Tue, 13 Jan 2026 14:00:00 GMT</pubDate>
<description>Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient populationATLANTA , Jan. 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Refuah Health Center to offer FemaSeed as a first step in the infertility treatment process. The partnership is</description>
</item>
<item>
<title>Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-secures-u-fda-clearance-141500702</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-secures-u-fda-clearance-141500702</guid>
<pubDate>Thu, 18 Dec 2025 14:15:00 GMT</pubDate>
<description>-- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support fallopian tube evaluation and improve workflow efficiency-- ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its FemVue Con</description>
</item>
<item>
<title>Femasys Announces Third Quarter Financial Results for 2025</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-announces-third-quarter-financial-210100130</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-announces-third-quarter-financial-210100130</guid>
<pubDate>Fri, 14 Nov 2025 21:01:00 GMT</pubDate>
<description>– FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway – ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the third quarter of 2025. Corporate Highlights from 3Q 2025 An</description>
</item>
<item>
<title>Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-advances-global-growth-second-140000438</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-advances-global-growth-second-140000438</guid>
<pubDate>Mon, 10 Nov 2025 14:00:00 GMT</pubDate>
<description>-- Continued rollout of FemBloc, the breakthrough non-surgical permanent contraceptive solution, expands the Company’s presence in key European Markets -- ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, today announced a significant initial order valued at approximately $500,000 USD for the commercial launch of FemBloc Permanent B</description>
</item>
<item>
<title>Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-secures-fda-approval-advance-133000263</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-secures-fda-approval-advance-133000263</guid>
<pubDate>Mon, 03 Nov 2025 13:30:00 GMT</pubDate>
<description>-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured convertible notes for total potential proceeds of $58 million, if all warrants are exercised for cash, reflecting strong investor confidence in Femasys’ women’s health mission -- ATLANTA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and no</description>
</item>
<item>
<title>Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-announces-initiation-post-market-130000754</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-announces-initiation-post-market-130000754</guid>
<pubDate>Wed, 22 Oct 2025 13:00:00 GMT</pubDate>
<description>--Marks key milestone in European commercialization strategy under EU Medical Device Regulation (MDR)-- ATLANTA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced the commencement of a post-market surveillance (PMS) clinical study for its CE-marked FemBloc Permanent Birth Control. This study is being conducted in accordance with th</description>
</item>
<item>
<title>Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-exhibit-asrm-2025-scientific-130000536</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-exhibit-asrm-2025-scientific-130000536</guid>
<pubDate>Thu, 16 Oct 2025 13:00:00 GMT</pubDate>
<description>Will Showcase Latest Fertility SolutionsSAN ANTONIO, Texas, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, is pleased to announce that it will exhibit at the American Society for Reproductive Medicine (ASRM) 2025 Scientific Congress & Expo, which will take place October 25-29 at the Henry B. González Convention Center in San Antonio, Texa</description>
</item>
<item>
<title>Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-accelerates-european-growth-fembloc-130000402</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-accelerates-european-growth-fembloc-130000402</guid>
<pubDate>Thu, 25 Sep 2025 13:00:00 GMT</pubDate>
<description>-- Femasys leverages Kebomed’s pan-European distribution strength to drive adoption of FemBloc permanent birth control in France and Benelux, unlocking significant market access --ATLANTA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Kebomed, a leading European distributor of medical devices and equip</description>
</item>
<item>
<title>Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed</title>
<link>https://6ix.com/company/femasys-inc/news/femasys-partners-medical-electronic-systems-130000339</link>
<guid isPermaLink="true">https://6ix.com/company/femasys-inc/news/femasys-partners-medical-electronic-systems-130000339</guid>
<pubDate>Mon, 22 Sep 2025 13:00:00 GMT</pubDate>
<description>Addition strengthens FemSperm family of products and enables gynecologists to offer complete in-office sperm handling for FemaSeed Intratubal InseminationATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Medical Electronic Systems LLC (MES) to provide advanced sperm analysis technology. The FemSpe</description>
</item>
</channel>
</rss>